Status:
COMPLETED
Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients
Lead Sponsor:
University Hospital, Montpellier
Conditions:
SARS-Cov-2 Infection
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
Immune aging or immunosenescence is characterized by a loss of T cell clonal diversity and a contraction of naïve T cells with proliferative capacity associated with the functional impairment of many ...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Active RA Patients:
- Patients with rheumatoid arthritis (RA) meeting the 2010 ACR/EULAR diagnostic criteria
- Patients in inflammatory flare of RA (DAS28 \> 3.2)
- Patients who have been off biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic antirheumatic drugs (tsDMARDs) for RA for at least 2 weeks (except for rituximab, where a delay of at least 12 months is required)
- Conventional synthetic DMARDs (Methotrexate, Hydroxychloroquine, Leflunomide, Sulfasalazine) are allowed
- Beneficiary of a social security system
- Informed consent
- Inclusion Criteria for Healthy Controls:
- Absence of chronic diseases and current infection
- Beneficiary of a social security system
- Informed consent
- Inclusion Criteria for COVID-19+ Patients:
- Patients with ongoing SARS-Cov-2 infection (PCR+)
- Patients hospitalized at D7-D14 of symptoms onset
- Patients with two or more SARS-Cov-2 symptoms (including fever, cough, dyspnea, sore throat, chest pain, anosmia, diarrhea)
- Membership in or beneficiary of a social security scheme
- Collection of free and informed consent
- Exclusion Criteria for All Groups:
- Subjects under 18 years of age
- HIV positive patients
- Diabetic patients
- Morbidly obese patients (BMI \> 40kg/m2)
- Use of senolytic drugs in the week prior to inclusion (azithromycin, metformin, cyclosporine, JAK inhibitors)
- Use of steroids in doses greater than 10 mg/day in the week prior to inclusion
- Subjects unable to give consent
- Pregnant, breastfeeding, or non-menopausal women not taking effective contraception
- Vulnerable subjects protected by law
- Subjects under guardianship or curatorship
Exclusion
Key Trial Info
Start Date :
July 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 16 2022
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04880720
Start Date
July 19 2021
End Date
November 16 2022
Last Update
January 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Montpellier
Montpellier, France, 34080